For more information regarding Bristol-Myers Squibb Clinical Trial participation,please
visit www.BMSStudyConnect.com.
Inclusion Criteria:
- Participants with a primary diagnosis of melanoma with involvement of lymph nodes or
metastatic disease who have undergone complete resection and have no evidence of
disease
- Decision to treat with adjuvant nivolumab therapy has already been taken
- Participants who provide oral informed consent to participate in the study
Exclusion Criteria:
- Any participant with a current diagnosis of persisting advanced melanoma
- Participants with a current primary diagnosis of a cancer other than advanced
melanoma, ie, a cancer other than melanoma that requires systemic or other treatment
or has not been treated curatively (as per discretion of the investigator)
- Any participants currently enrolled in an interventional clinical trial for his/her
melanoma treatment (note: patients who have completed their participation in an
interventional trial or who are no longer receiving the study drug and are only
followed up for OS/RFS can be enrolled. In case of a blinded study, the treatment arm
needs to be known).
- Pregnant women
- Person under guardianship
Other protocol defined inclusion/exclusion criteria apply
Active, Not Recruiting
